González CO, García LSMC

Idioma: Español
Referencias bibliográficas: 83
Paginas: 249-260
Archivo PDF: 96.88 Kb.

RESUMEN

La vasopresina, es secretada a nivel de la neurohipófisis siendo influida por un gran número de variables, entre ellas, las más importantes y conocida es la presión osmótica del agua corporal. Otros factores que modifican la liberación de esta hormona, lo constituyen los cambios en el volumen sanguíneo y presión arterial, contribuyendo de manera importante a la recuperación hemodinámica. Los receptores de vasopresina tienen diferentes localizaciones y son divididos en V1 y V2, cuya estimulación resulta en diferentes respuestas fisiológicas. Con base en las antes mencionadas, el uso de la vasopresina de manera exógena ha sido probado en diferentes situaciones clínicas, como lo son: el paro cardíaco refractario a tratamiento, choque séptico, choque vasodilatador, choque postcardiotomía y síndrome vasopléjico con resultados promisorios. Actualmente existe el sustento científico suficiente para la utilización de esta hormona en la práctica clínica.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gaitan E, Cobo E, Mizrachi M: Evidence for the differential secretion of oxytocin and vasopressin in man. J Clin Invest 1964; 43: 2310-2313.

2. Robertson GL, Atar S, Shelton RL: Osmotic control of vasopressin function: disturbances in body fluid osmolality. Bethesda, American Physiological Society: 1997: 125-130.

3. Robertson GL, Atar S: The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 1976; 42: 613-619.

4. Jonson JA: Effects of separate and concurrent osmotic and volume stimuli on plasma ADH in sheep. Am J Physiol 1970; 128: 1273-1276.

5. Robertson GL: Development and clinical application of a new method for the radioimmunoassay of arginin vasopressin in human plasma. J Clin Invest 1973; 52: 2340-2345.

6. Malayan S: Effects of increases in plasma vasopressin concentration on plasma renin activity, blood pressure, heart rate and plasma corticosteroid concentration in dogs. Endocrinology, 1980; 107: 1899-1904.

7. Zerbe RL: Vasopressin: an essential pressor factor for blood pressure recovery following hemorrhage. Peptides 1982; 3: 509-511.

8. Dunn FL: The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973; 52: 3212-3216.

9. Robertson GL: The role of osmotic and hemodynamic variables in regulation vasopressin, in James VHT. Proceeding of the fifth International Congress of Endocrinology, Hamburg, July 1976, Excerpta Medic Congress Series no. 402. Amsterdam, 1977: 126-136.

10. Kannan H, Yagi R: Supraoptic neurosecretory neurons: evidence for the existence of converging inputs both from carotid baroreceptors and osmoreceptors. Brain Res 1978; 145: 385-392.

11. Jun ER: Cholinergic and adrenergic release mechanism for vasopressin in the male rat: a study with injection of neurotransmitters and blocking agents into the third ventricle. Neuroendocrinology1974; 16: 255-260.

12. Share L: Extracellular fluid volume and vasopressin secretion. In: Ganong WF, Martini L. Frontiers in neuroendocrinology. New York, Oxford University Press. 1969: 183-189.

13. Sawchenko PE, Swanson LW: Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses. Science 1981; 214: 685-689.

14. Thibonnier M, Conarty DM, Presston JA: Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998; 449: 251-276.

15. Thibonnier M, Berti-Mattera LN, Dulin N, Materra R: Signal transduction pathways of the human V1 vascular, V2 renal, V3 pituitary vasopressin and oxytocin receptors. Prog Brain Res 1998; 119: 147-161.

16. Morel F: Sites of hormone action in the mammalian nephron. Am J Physiol 1981; 240: F159-F164.

17. Nielsen S, Marples D, Frokiaer J: The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin 2. Kidney Int 1996; 49: 1718-1723.

18. Bankir L: Antidiuretic action of vasopressin: quantitative aspects and interaction between V1 and V2 receptor-mediated effects. Cardiovascular Research 2001; 51: 372-390.

19. Kaufmann JE, Oksche A, Wollheim CB: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and camp. J Clin Invest 2000; 106: 107-116.

20. Richardson DW, Robinson AG: Desmopressin. Ann Internal Med 1985; 103: 228-239.

21. Rowe JW: Influence of the emetic reflex on vasopressin release in man. Kidney Int 1979; 16: 729-733.

22. Lindner KH, Strohmenger IU, Prengel AW, Ensinger H, Goertz A, Weichel T: Hemodynamic and metabolic effects of epinephrine during cardiopulmonary resuscitation in a pig model. Crit Care Med 1992; 20: 1020-1026.

23. Prengel AW, Lindner KH, Ensinger H, Grunert A: Plasma catecholamine concentrations after successful resuscitation in patients. Crit Care Med 1992; 20: 609-614.

24. Shen YT, Cowley AW, Vatner SF: Relative roles of cardiac and arterial baroreceptors in vasopressin regulation during hemorrhage in conscious dogs. Cir Res 1991; 68: 1422-1423.

25. Wilson MF, Brackett DJ: Release of vasoactive hormones and circulatory changes in shock. Cir Shock 1983; 11: 225-234.

26. Miller RC, Pelton JT, Huggins JP: Endothelins from receptors to medicine. Trends Pharmacol Sci 1993; 14: 54-60.

27. Ota K, Kimura T, Shoji M, Inoue M, Sato K, Ohta M: Interaction of ANP with endothelium on cardiovascular, renal, endocrine function. Am J Physiol 1992; 262: EI 135-141.

28. Lindner KH, Haak T, Kéller A, Bothner U, Lurie KG: Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 1996; 75(2): 145-150.

29. Schultz CH, Rivers EP, Fwldkamo CS, Goad EG, Smithline HA, Martín GB: A characterization of hypothalamic-pituitary-adrenal axis function during and after human cardiac arrest. Crit Care Med 1993; 21: 1339-1347.

30. Lindner KH, Brinkmann A, Pfenninger EG, Lurie KG, Goertz A, Lindner MI: Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg 1993; 77: 427-435.

31. Lindner KH, Prengel AW, Pfenniger EG, Lindner MI, Strohmenger H-U, Georgieff M: Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91: 215-221.

32. Lindner KH, Prengel AW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG: Vasopressin administration in refractory cardiac arrest. Ann Inter Med 1996; 124(12): 1061-1064.

33. Brown CG, Martín DR, Pepe PE, Stueven H, Cummins RO, González E, Jastremski MA: A comparison of standard-dose and high-dose in cardiac arrest outside the hospital. N Engl J Med 1992; 327: 1051-1055.

34. Eichinger MR, Walker BR: Enhanced pulmonary arterial dilatation to arginine vasopressin in the chronically hypoxic rat. Am J Physiol 1994; 267: H2413-H2429.

35. Russ RD, Walker BR: Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 1992; 263: H743-H747.

36. Evora PR, Pearson PJ, SCAF HB: Arginin vasopressin induces endothelium-dependent vasodilatation in the pulmonary artery: V1 receptor mediated production of nitric oxide. Chest 1995; 103: 1241-1243.

37. Chandrashekhar Y, Anand I, Goldsmith S: Arginine vasopressin V1-a receptor mediates positives inotropic effects in normal isolated rat cardiac myocytes. Circulation 1994; 90: (suppl 1): 1-174.

38. Chung S, Lurie K, Lindner K: Pressor with promise: using vasopressin in cardiopulmonary arrest. Circulation 1997; 96(7): 2453-2454.

39. Lindner KH, Strohmeenger UH, Endinger H: Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 1992; 77: 662-668.

40. Babar SI, Berg RA, Hilwing RW, Kern KB, Ewy GA: Vasopressin versus epinephrine during cardiopulmonary resuscitation: a randomized swine outcome study. Resuscitation 1999; 41: 185-192.

41. Wenzel V, Lindner KH, Prengel AW, Maier C, Voelckel W, Lurie KG, Strohmenger HU: Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcounter shock pulseless electrical activity in pigs. Crit Care Med 1999; 27: 486-492.

42. Prengel AW, Lindner KH, Séller A, Lurie KG: Cardiovascular function during the postresuscitation phase after cardiac arrest in pigs: a comparison of epinephrine versus vasopressin. Crit Care Med 1996; 24: 2014-2019.

43. Fox AW, May RE, Mitch WE: Comparison of peptide and nonpeptide receptor-mediated responses in rat-tail artery. J Cardiovasc Pharmacol 1992; 20: 282-289.

44. Wenzel V, Lindner KH, Baubin MA: Vasopressin decrease endogenous catecholamine plasma levels during cardiopulmonary resuscitation in pigs. Crit Care Med 2000; 28: 1096-1100.

45. Lindner KH, Dirks B, Strohmenger HU: Randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535-537.

46. Guidelines 2000 for cardiopulmonary resuscitation end emergency cardiovascular care. Circulation 2000; 102(suppl I): I-129-135.

47. Kern KB, Halperin HR, Fcield J: New guidelines for cardiopulmonary resuscitation and emergency cardiac care: changes in the management of cardiac arrest. JAMA 2001; 285(10): 1267-1269.

48. Stiell IG, Hebert PC, Wells WA, Vandemheen KL, Tang AS, Higginson LA: Vasopressin versus epinephrine for intrahospital cardiac arrest: a randomized controlled trial. LANCET 2001; 358: 105-109.

49. Wenzel V, Lindner KH, Prengel AW: Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs. Anesthesiology 1997; 86: 1375-1381.

50. Wenzel V, Lindner KH, Augenstein S: Intraosseus vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 1999; 27: 1565-1569.

51. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Cunnion RE, Ognibene FP: Septic Shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990; 13: 227-242.

52. Glauser MP, Zanetti G, Baumgarthener JD, Coheen J: Septic shock: pathogenesis. Lancet 1991; 338: 732-736.

53. Suffrendini AF, Frome WL, Parker NM, Breenneeer M, Kovascs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to administration of endotoxin. N Engl J Med 1989; 321: 280-287.

54. Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.

55. Petros A, Bennet D, Vaallancee P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-1558.

56. Landry DW, Oliver JA: The ATP-sensitive K sup channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89: 2071-2074.

57. Reid IA: Role of vasopressinin deficiency in the vasodilation of septic shock. Circulation 1997; 95: (5): 1108-1110.

58. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alesandro D, et al: Vasopressin deficiency contributes to the vasodilatation of septic shock. Circulation 1997; 95: 1122-1125.

59. Tsuneyoshi I, Yamada H, Kakihana Y, Masataka N, Nakano Y, Boyle WA: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29(3): 487-493.

60. Abid O, Akca S, Haji-Michael P: Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med 2000; 28: 947-949.

61. Benedict CR, Rose JA: Arterial norepinephrine changes in patients with shock septic. Circ Shock 1992; 38: 165-167.

62. Byrne JJ: Shock. N Engl J Med 1996; 275: 543-546.

63. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-1477.

64. Bernard GR, Wheeler AP, Russell JA: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912-918.

65. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595.

66. Morales D, Madiagan J, Cullinace S: Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226-229.

67. Argenziano M, Choudhri F, Oz MC, Rose EA, Smith CR, Landry DW: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96: (Suppl II): 286-290.

68. Cowley AW Jr, Monos E, Guyton AC: Interaction of vasopressin and baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34: 505-514.

69. Bartelstone HJ, Nasmyth PA: Vasopressin potentiation of catecholamine actions in dogs, rat, cat and rat aortic strip. Am J Physiol 1965; 208: 754-762.

70. Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, Oz MC: Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69: 102-106.

71. Rosenzweig EB, Starc TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM, et al: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100: (II): 182-186.

72. Mager G, Klocke R: Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as analternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991; 121: 1974-1983.

73. Seino Y, Momomura S, Tenako T: Multicenter double blind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med 1996; 24: 1490-1497.

74. Gold JA, Cullinane S, Chen J, Oz MC, Oliver JA, Landry DW: Vasopressin as an alternative to norepinephrine in the treatment of milrinone induced hypotension. Crit Care Med 2000; 28: 249-252.

75. Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989Z; 256: F274-278.

76. Wagner HN, Braunwald E: The pressor effects of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 1956; 35: 1412-1418.

77. Goldsmith SR, Francis GS, Cowley AW, Goldenberg IF, Cohn JN: Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986; 8: 779-783.

78. Walkerk BR, Childs ME, Adams EM: Direct cardiac effects of vasopressin: role of V1 and V2 vasopressinergic receptors. Am J Physiol 1988; 255: H261 H 265.

79. Boyle QA III, Segel LD: Direct cardiac effects of vasopressin and their reversal by vascular antagonist. Am J Physiol 1986; 251: H734-H741.

80. Dunser MW, Mayr AJ, Ulmer H, Ritsch, Knotzer H, Palk W, et al: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7-13.

81. Mekontso-Dessap A, Houël R, Soustelle C, Kirsch M, Thebert D, Loisance DY: Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001; 71: 1428-1432.

82. Kirklin JK: Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 1991; 51: 529-531.

83. Argenziano M, Chen JM, Choudhri AF: Management of vasodilatory shock after cardiac surgery: the systemic inflammatory response. Ann Thorac Surg 1997; 63: 277-284.